IR 902

Drug Profile

IR 902

Alternative Names: AI 208; IR-208; Multiple sclerosis vaccine - Immune Response BioPharma; NeuroVax; V beta 17

Latest Information Update: 12 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Response Corporation
  • Developer Immune Response BioPharma; Orchestra Therapeutics
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 12 Aug 2015 Phase-II development for Multiple sclerosis is ongoing in USA
  • 06 Jan 2015 IR 902 is available for licensing as of 06 January 2015
  • 17 Jul 2014 Immune Response BioPharma plans a phase I trial for Multiple sclerosis in USA (NCT02200718)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top